Novartis announces portfolio transformation, focusing company on leading businesses with innovation power and global scale: Pharmaceuticals, Eye Care and Generics

  • Acquires GSK oncology products, strengthening Novartis’ leading Oncology business with novel therapies and becomes GSK’s preferred commercialization partner for its oncology pipeline
  • Combines Novartis OTC with GSK’s consumer business in a joint venture, creating a world-leading consumer healthcare business and maintaining Novartis’ presence in in this sector
  • Divests Vaccines business (excluding flu) to GSK, creating a global leader in vaccines
  • In a separate transaction, divests Novartis Animal Health to Lilly

Transactions improve Novartis’ …

/by

Novartis appoints Jeff George as Division Head, Alcon as Kevin Buehler retires; Richard Francis named as new Division Head, Sandoz

Basel, April 9, 2014 – New leaders to continue to build global scale and innovation power in two of the leading Novartis businesses

Novartis announced today the appointment of Jeff George as Division Head of Alcon, effective May 1, 2014. Mr. George succeeds Kevin Buehler who is retiring from the company after a distinguished 30 year career at Alcon, the global leader in eye care. As part of the planned transition, Mr. Buehler will provide management and strategic support on the Alcon business. The company thanks Mr. Buehler for his significant contributions to …

/by

Sandoz launches first generic version of Taclonex® Ointment

Princeton, New Jersey, April 1, 2014 – Sandoz today announced the US market introduction of its calcipotriene and betamethasone dipropionate ointment, the first generic version of Leo Pharma’s Taclonex® Ointment.

​Calcipotriene and betamethasone dipropionate ointment is a vitamin D analogue and corticosteroid combination product indicated for the topical treatment of psoriasis vulgaris in adults 18 years of age and older.

Psoriasis affects approximately 2% of the US population. Plaque psoriasis is the most common form of the condition. [1]

“Sandoz is …

/by

Sandoz launches AirFluSal® Forspiro® in Norway

Holzkirchen, April 2, 2014 – Sandoz announces today that it is launching in Norway AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

​The product was first approved in Denmark on December 18th, 2013, with subsequent approvals in Germany, Belgium, Sweden, Hungary, Romania and Bulgaria. In February, Sandoz received its first marketing approval in Asia, with marketing authorization in South Korea.

In Norway, Sandoz is launching the 50/250µg and 50/500µg dosage forms for the continuous …

/by

Sandoz launches generic version of PREVPAC® in the US

Princeton, New Jersey, March 27, 2014 – Sandoz today announced the US launch of lansoprazole capsules, amoxicillin capsules, USP, and clarithromycin tablets, USP, a generic version of PREVPAC®1.

​This product is indicated for the eradication of H. pylori infection in patients with duodenal ulcer disease. It comprises amoxicillin and clarithromycin, which are antibiotic medicines, as well as lansoprazole, a proton pump inhibitor that helps decrease production of excess stomach acid2.

“Sandoz is proud to provide a generic version of this …

/by

Vas Narasimhan to lead Sandoz’biosimilars business

Munich, Germany, March 27, 2014 – Sandoz announced today that Vasant (Vas) Narasimhan, MD, MPP, has been appointed Head of Sandoz Biopharmaceuticals & Oncology Injectables effective April 1, 2014. Vas, currently Global Head of Development at Novartis Vaccines, succeeds Ameet Mallik who will take on a new leadership role at Novartis Oncology. Vas will be responsible for biosimilars, oncology injectables, the biotechnology contract manufacturing business, as well as Sandoz’ industry-leading biosimilars pipeline.

“I am deeply grateful for Ameet’s outstanding …

/by

Sandoz receives approval for biosimilar filgrastim in Japan

  • Sandoz Filgrastim approved in all indications as the reference product
  • Sandoz becomes first company to secure approval for two biosimilars in Japan
  • Approval marks continued expansion of Sandoz’ biosimilar business
…
/by

Tuberculosis remains a global health challenge; Sandoz continues commitment to fighting the disease

March 21, 2014 – Despite great progress made in the fight to eradicate Tuberculosis (TB), the disease remains a global killer and disproportionately affects the world’s poor. Sandoz, a leading provider of high-quality, affordable generic medicines, has the opportunity to significantly contribute to the fight against TB.

Tuberculosis (TB) is second only to HIV/AIDS as the greatest killer worldwide due to a single infectious agent, according to the World Health Organization. In 2012, 8.6 million people fell ill with TB and 1.3 million died from TB.

…

/by

Sandoz expands Tuberculosis activities in Africa

March 19, 2014 – The Sandoz Tuberculosis (TB) program is increasing its reach in Africa. Sandoz is expanding its Tuberculosis portfolio as well as its Corporate Responsibility initiatives to support positive health outcomes for more patients and ultimately, contribute towards the eradication of the disease.

Sandoz contributes to fighting Tuberculosis in Egypt

In Egypt, TB constitutes the second most important public health problem, after schistosomiasis. Although Egypt has relatively low levels of TB according to data from the World Health …

/by

Sandoz expands Tuberculosis activities in Africa

March 19, 2014 – The Sandoz Tuberculosis (TB) program is increasing its reach in Africa. Sandoz is expanding its Tuberculosis portfolio as well as its Corporate Responsibility initiatives to support positive health outcomes for more patients and ultimately, contribute towards the eradication of the disease.

Sandoz contributes to fighting Tuberculosis in Egypt

In Egypt, TB constitutes the second most important public health problem, after schistosomiasis. Although Egypt has relatively low levels of TB according to data from the World Health …

/by